Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909298 · ClinicalTrials.gov registry record · Phase 2
Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)
A Phase 2 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00909298 is a Phase 2 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT00909298, a Phase 2 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if post-operative administration of intrinsic pathway antagonist (TTP889) in patients on Left Ventricular Assist Device (LVAD) support will result in a 50% reduction of thrombin generation markers at 28 days compared to placebo.
Interventions
- DRUG Placebo
- DRUG TTP889
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909298
The ClinicalTrials.gov registry entry for NCT00909298 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00909298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909298 about?
NCT00909298 is a clinical study titled "Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)". The purpose of this study is to determine if post-operative administration of intrinsic pathway antagonist (TTP889) in patients on Left Ventricular Assist Device (LVAD) support will result in a 50% reduction of thrombin generation markers at 28 days compared to placebo.
What is the current status of trial NCT00909298?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00909298?
The interventions under investigation include: Placebo (DRUG), TTP889 (DRUG).
Who is sponsoring clinical trial NCT00909298?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.